Login to Your Account

in the clinic NEWS
Shares of Targacept Inc. (NASDAQ:TRGT) fell to a 52-week low of $2.76 Tuesday after the company disclosed late Monday that it was sacking lead compound TC-5214 in the treatment of overactive bladder (OAB) after top-line phase IIb findings failed to show statistical significance in improving urinary incontinence.
Merck & Co. Inc. enrolled the first patient in a global phase III study of letermovir (MK-8228, AIC246), an experimental cytomegalovirus (CMV) antiviral it licensed from Aicuris GmbH.
Three months ago, Puma Biotechnology Inc. ran into Wall Street headwinds on findings from its adaptive I-SPY 2 (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2) trial of PB272 (neratinib), a pan-HER tyrosine kinase inhibitor, as neoadjuvant therapy in metastatic breast cancer.
More in the clinic Headlines

Cast Your Vote

Has biotech’s bubble burst?: